{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:25:31Z","timestamp":1789053931651,"version":"build-2803163510"},"reference-count":139,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,15]],"date-time":"2021-02-15T00:00:00Z","timestamp":1613347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Hugh Green Foundation, Auckland"},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["SAF-94814"],"award-info":[{"award-number":["SAF-94814"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Subst Abuse Treat Prev Policy"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In the early 2000s, increasing prevalence of psycho-stimulant (e.g., crack\/cocaine, methamphetamine) use and related harms, including severe adverse health outcomes, was observed among - mostly marginalized - populations of persons using illicit drugs in North America, underscoring an urgent need for interventions options towards improved prevention and treatment. By about 2010, however, the \u2018opioid crisis\u2019, featuring unprecedented use and public health burden, had accelerated into full force in North America, largely muting attention to the psycho-stimulant issue until recently. Recent surveillance data on drug use and related mortality\/morbidity from the present decade has documented a marked resurgence of psycho-stimulant use and harms especially in at-risk populations, commonly in direct combination with opioids, across North America, resulting in a \u2018twin epidemic\u2019 comprised of opioids and psycho-stimulants We briefly review select epidemiological data indicators for these developments from the United States and Canada; in the latter jurisdiction, related evidence has been less prevalent and systematic but corroborating the same trends. Evidently, the (widely ongoing) focus on the \u2018opioid epidemic\u2019 as a \u2018mono-type\u2019 drug problem has become an anachronism that requires urgent and appropriate correction. We then briefly consider existing, evidence-based options for \u2013 prevention and treatment \u2013 interventions targeting psycho-stimulant use and harms, which are substantially more limited and\/or less efficacious than those\u00a0available\u00a0for problematic opioid use,\u00a0while\u00a0presenting major gaps and challenges. The observed resurgence of psycho-stimulants may, indirectly, relate to recent efforts towards curtailing (medical) opioid availability, thereby accelerating demand and supply for both illicit opioids and psycho-stimulants. The presently unfolding \u2018twin epidemic\u2019 of opioids and psycho-stimulants, combined with limited intervention resources, presents an acute challenge for public health and may crucially undermine actively extensive efforts to reduce opioid-related health harms in North America.<\/jats:p>","DOI":"10.1186\/s13011-021-00350-5","type":"journal-article","created":{"date-parts":[[2021,2,17]],"date-time":"2021-02-17T14:23:12Z","timestamp":1613571792000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["\u2018Resurgent\u2019, \u2018twin\u2019 or \u2018silent\u2019 epidemic? A select data overview and observations on increasing psycho-stimulant use and harms in North America"],"prefix":"10.1186","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2186-4030","authenticated-orcid":false,"given":"Benedikt","family":"Fischer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"O\u2019Keefe-Markman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelica","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9352-2873","authenticated-orcid":false,"given":"Dimitri","family":"Daldegan-Bueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,15]]},"reference":[{"issue":"3","key":"350_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1080\/09595230801919460","volume":"27","author":"JC Maxwell","year":"2008","unstructured":"Maxwell JC, Rutkowski BA. The prevalence of methamphetamine and amphetamine abuse in North America: a review of the indicators, 1992\u20132007. Drug Alcohol Rev. 2008;27(3):229\u201335.","journal-title":"Drug Alcohol Rev"},{"issue":"12","key":"350_CR2","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1111\/j.1360-0443.2006.01614.x","volume":"101","author":"B Fischer","year":"2006","unstructured":"Fischer B, Rehm J, Patra J, Kalousek K, Haydon E, Tyndall M, et al. Crack across Canada: comparing crack users and crack non-users in a Canadian multi-city cohort of illicit opioid users. Addiction. 2006;101(12):1760\u201370.","journal-title":"Addiction."},{"issue":"1","key":"350_CR3","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/j.1465-3362.2011.00299.x","volume":"31","author":"E Roy","year":"2012","unstructured":"Roy E, Arruda N, Vaillancourt E, Boivin JF, Morissette C, Leclerc P, et al. Drug use patterns in the presence of crack in downtown Montr\u00e9al. Drug Alcohol Rev. 2012;31(1):72\u201380.","journal-title":"Drug Alcohol Rev"},{"issue":"3","key":"350_CR4","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1111\/j.1465-3362.2009.00145.x","volume":"29","author":"D Werb","year":"2010","unstructured":"Werb D, Debeck K, Kerr T, Li K, Montaner J, Wood E. Modelling crack cocaine use trends over 10 years in a Canadian setting. Drug Alcohol Rev. 2010;29(3):271\u20137.","journal-title":"Drug Alcohol Rev"},{"issue":"9","key":"350_CR5","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1111\/j.1360-0443.2007.01963.x","volume":"102","author":"B Fischer","year":"2007","unstructured":"Fischer B, Coghlan M. Crack use in north American cities: the neglected 'epidemic'. Addiction. 2007;102(9):1340\u20131.","journal-title":"Addiction."},{"issue":"9","key":"350_CR6","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1503\/cmaj.082054","volume":"181","author":"K DeBeck","year":"2009","unstructured":"DeBeck K, Kerr T, Li K, Fischer B, Buxton J, Montaner J, et al. Smoking of crack cocaine as a risk factor for HIV infection among people who use injection drugs. Can Med Assoc J. 2009;181(9):585\u20139.","journal-title":"Can Med Assoc J"},{"issue":"4","key":"350_CR7","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.drugpo.2009.12.008","volume":"21","author":"V Bungay","year":"2010","unstructured":"Bungay V, Johnson JL, Varcoe C, Boyd S. Women's health and use of crack cocaine in context: structural and 'everyday' violence. Int J Drug Policy. 2010;21(4):321\u20139.","journal-title":"Int J Drug Policy"},{"issue":"6","key":"350_CR8","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1097\/00002030-200304110-00014","volume":"17","author":"MW Tyndall","year":"2003","unstructured":"Tyndall MW, Currie S, Spittal P, Li K, Wood E, O'Shaughnessy MV, et al. Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic. Aids. 2003;17(6):887\u201393.","journal-title":"Aids."},{"key":"350_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1477-7517-10-29","volume":"10","author":"P Duff","year":"2013","unstructured":"Duff P, Tyndall M, Buxton J, Zhang R, Kerr T, Shannon K. Sex-for-crack exchanges: associations with risky sexual and drug use niches in an urban Canadian city. Harm Reduct J. 2013;10:29.","journal-title":"Harm Reduct J"},{"issue":"2","key":"350_CR10","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.drugpo.2012.10.004","volume":"24","author":"\u00c9 Roy","year":"2013","unstructured":"Roy \u00c9, Richer I, Arruda N, Vandermeerschen J, Bruneau J. Patterns of cocaine and opioid co-use and polyroutes of administration among street-based cocaine users in Montr\u00e9al, Canada. Int J Drug Policy. 2013;24(2):142\u20139.","journal-title":"Int J Drug Policy"},{"issue":"6","key":"350_CR11","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1111\/j.1360-0443.2010.02932.x","volume":"105","author":"BD Marshall","year":"2010","unstructured":"Marshall BD, Werb D. Health outcomes associated with methamphetamine use among young people: a systematic review. Addiction. 2010;105(6):991\u20131002.","journal-title":"Addiction."},{"issue":"1","key":"350_CR12","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1477-7517-3-18","volume":"3","author":"E Wood","year":"2006","unstructured":"Wood E, Stoltz J-A, Montaner JSG, Kerr T. Evaluating methamphetamine use and risks of injection initiation among street youth: the ARYS study. Harm Reduct J. 2006;3(1):18.","journal-title":"Harm Reduct J"},{"issue":"1\u20132","key":"350_CR13","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.drugalcdep.2011.05.012","volume":"119","author":"BDL Marshall","year":"2011","unstructured":"Marshall BDL, Galea S, Wood E, Kerr T. Injection methamphetamine use is associated with an increased risk of attempted suicide: a prospective cohort study. Drug Alcohol Depend. 2011;119(1\u20132):134\u20137.","journal-title":"Drug Alcohol Depend"},{"issue":"2\u20133","key":"350_CR14","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.drugalcdep.2006.10.019","volume":"88","author":"N Fairbairn","year":"2007","unstructured":"Fairbairn N, Kerr T, Buxton JA, Li K, Montaner JS, Wood E. Increasing use and associated harms of crystal methamphetamine injection in a Canadian setting. Drug Alcohol Depend. 2007;88(2\u20133):313\u20136.","journal-title":"Drug Alcohol Depend"},{"key":"350_CR15","volume-title":"Methamphetamine report for federal-provincial territorial ministers responsible for justice","author":"Department of Justice","year":"2007","unstructured":"Department of Justice. Methamphetamine report for federal-provincial territorial ministers responsible for justice. Ottawa: Department of Justice Canada; 2007."},{"issue":"3","key":"350_CR16","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/BF03404893","volume":"102","author":"LA Malchy","year":"2011","unstructured":"Malchy LA, Bungay V, Johnson JL, Buxton J. Do crack smoking practices change with the introduction of safer crack kits? Can J Public Health. 2011;102(3):188\u201392.","journal-title":"Can J Public Health"},{"issue":"4","key":"350_CR17","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.drugpo.2011.05.005","volume":"22","author":"A Ivsins","year":"2011","unstructured":"Ivsins A, Roth E, Nakamura N, Krajden M, Fischer B. Uptake, benefits of and barriers to safer crack use kit (SCUK) distribution programmes in Victoria, Canada - a qualitative exploration. Int J Drug Policy. 2011;22(4):292\u2013300.","journal-title":"Int J Drug Policy"},{"key":"350_CR18","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1747-597X-6-4","volume":"6","author":"K DeBeck","year":"2011","unstructured":"DeBeck K, Buxton J, Kerr T, Qi J, Montaner J, Wood E. Public crack cocaine smoking and willingness to use a supervised inhalation facility: Implications for street disorder. Subst Abuse Treat Prev Policy. 2011;6:4.","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"5","key":"350_CR19","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.drugpo.2009.11.007","volume":"21","author":"L Degenhardt","year":"2010","unstructured":"Degenhardt L, Mathers B, Guarinieri M, Panda S, Phillips B, Strathdee SA, et al. Meth\/amphetamine use and associated HIV: implications for global policy and public health. Int J Drug Policy. 2010;21(5):347\u201358.","journal-title":"Int J Drug Policy"},{"issue":"2","key":"350_CR20","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s11121-010-0197-y","volume":"12","author":"BD Marshall","year":"2011","unstructured":"Marshall BD, Wood E, Shoveller JA, Buxton JA, Montaner JS, Kerr T. Individual, social, and environmental factors associated with initiating methamphetamine injection: implications for drug use and HIV prevention strategies. Prev Sci. 2011;12(2):173\u201380.","journal-title":"Prev Sci"},{"issue":"1","key":"350_CR21","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jsat.2014.07.002","volume":"48","author":"P Mateu-Gelabert","year":"2015","unstructured":"Mateu-Gelabert P, Guarino H, Jessell L, Teper A. Injection and sexual HIV\/HCV risk behaviors associated with nonmedical use of prescription opioids among young adults in New York City. J Subst Abus Treat. 2015;48(1):13\u201320.","journal-title":"J Subst Abus Treat"},{"issue":"3 Suppl","key":"350_CR22","doi-asserted-by":"publisher","first-page":"Es191","DOI":"10.36076\/ppj.2012\/15\/ES191","volume":"15","author":"B Fischer","year":"2012","unstructured":"Fischer B, Argento E. Prescription opioid related misuse, harms, diversion and interventions in Canada: A review. Pain Physician. 2012;15(3 Suppl):Es191\u2013203.","journal-title":"Pain Physician"},{"issue":"1\u20132","key":"350_CR23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.drugalcdep.2012.03.010","volume":"126","author":"B Nosyk","year":"2012","unstructured":"Nosyk B, Marshall BD, Fischer B, Montaner JS, Wood E, Kerr T. Increases in the availability of prescribed opioids in a Canadian setting. Drug Alcohol Depend. 2012;126(1\u20132):7\u201312.","journal-title":"Drug Alcohol Depend"},{"issue":"9","key":"350_CR24","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.3109\/10826084.2011.552932","volume":"46","author":"E Roy","year":"2011","unstructured":"Roy E, Arruda N, Bourgois P. The growing popularity of prescription opioid injection in downtown Montr\u00e9al: new challenges for harm reduction. Subst Use Misuse. 2011;46(9):1142\u201350.","journal-title":"Subst Use Misuse"},{"key":"350_CR25","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.drugpo.2019.01.010","volume":"71","author":"D Ciccarone","year":"2019","unstructured":"Ciccarone D. The triple wave epidemic: supply and demand drivers of the US opioid overdose crisis. Int J Drug Policy. 2019;71:183\u20138.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"350_CR26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13011-020-0256-8","volume":"15","author":"B Fischer","year":"2020","unstructured":"Fischer B, Pang M, Jones W. The opioid mortality epidemic in North America: Do we understand the supply side dynamics of this unprecedented crisis? Subst Abuse Treat Prev Policy. 2020;15(1):14.","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"11","key":"350_CR27","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1503\/cmaj.060729","volume":"175","author":"B Fischer","year":"2006","unstructured":"Fischer B, Rehm J, Patra J, Firestone CM. Changes in illicit opioid use across Canada. Can Med Assoc J. 2006;175(11):1385.","journal-title":"Can Med Assoc J"},{"issue":"1","key":"350_CR28","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.drugalcdep.2007.08.008","volume":"92","author":"WR Davis","year":"2008","unstructured":"Davis WR, Johnson BD. Prescription opioid use, misuse, and diversion among street drug users in New York City. Drug Alcohol Depend. 2008;92(1):267\u201376.","journal-title":"Drug Alcohol Depend"},{"issue":"1\u20132","key":"350_CR29","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.drugalcdep.2012.12.027","volume":"132","author":"M Cerd\u00e1","year":"2013","unstructured":"Cerd\u00e1 M, Ransome Y, Keyes KM, Koenen KC, Tracy M, Tardiff KJ, et al. Prescription opioid mortality trends in New York City, 1990-2006: examining the emergence of an epidemic. Drug Alcohol Depend. 2013;132(1\u20132):53\u201362.","journal-title":"Drug Alcohol Depend"},{"issue":"9","key":"350_CR30","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1111\/add.13795","volume":"112","author":"DJ Hsu","year":"2017","unstructured":"Hsu DJ, McCarthy EP, Stevens JP, Mukamal KJ. Hospitalizations, costs and outcomes associated with heroin and prescription opioid overdoses in the United States 2001\u201312. Addiction. 2017;112(9):1558\u201364.","journal-title":"Addiction"},{"issue":"1","key":"350_CR31","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1186\/s12913-020-05530-w","volume":"20","author":"W Jones","year":"2020","unstructured":"Jones W, Kurdyak P, Fischer B. Examining correlations between opioid dispensing and opioid-related hospitalizations in Canada, 2007-2016. BMC Health Serv Res. 2020;20(1):677.","journal-title":"BMC Health Serv Res"},{"issue":"2","key":"350_CR32","doi-asserted-by":"publisher","first-page":"e180217","DOI":"10.1001\/jamanetworkopen.2018.0217","volume":"1","author":"T Gomes","year":"2018","unstructured":"Gomes T, Tadrous M, Mamdani MM, Paterson JM, Juurlink DN. The burden of opioid-related mortality in the United States. JAMA Netw Open. 2018;1(2):e180217\u2013e.","journal-title":"JAMA Netw Open"},{"issue":"5","key":"350_CR33","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1097\/ADM.0000000000000412","volume":"12","author":"T Gomes","year":"2018","unstructured":"Gomes T, Greaves S, Tadrous M, Mamdani MM, Paterson JM, Juurlink DN. Measuring the burden of opioid-related mortality in Ontario, Canada. J Addict Med. 2018;12(5):418\u20139.","journal-title":"J Addict Med"},{"key":"350_CR34","doi-asserted-by":"publisher","first-page":"290","DOI":"10.15585\/mmwr.mm6911a4","volume":"69","author":"N Wilson","year":"2020","unstructured":"Wilson N, Kariisa M, Seth P, Smith HI, Davis N. Drug and opioid-involved overdose deaths - United States, 2017\u20132018. Morb Mortal Wkly Rep. 2020;69:290\u20137.","journal-title":"Morb Mortal Wkly Rep"},{"issue":"2","key":"350_CR35","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1080\/09687637.2019.1645094","volume":"27","author":"L Vojtila","year":"2020","unstructured":"Vojtila L, Pang M, Goldman B, Kurdyak P, Fischer B. Non-medical opioid use, harms, and interventions in Canada \u2013 a 10-year update on an unprecedented substance use-related public health crisis. Drugs Educ Prev Policy. 2020;27(2):118\u201322.","journal-title":"Drugs Educ Prev Policy"},{"key":"350_CR36","unstructured":"Government of Canada. Opioid-related harms in Canada: Maps Canada: Government of Canada; 2020. Available from: https:\/\/health-infobase.canada.ca\/substance-related-harms\/opioids\/maps?index=15 [cited 2020 November, 30]."},{"issue":"11","key":"350_CR37","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1001\/jama.2017.9308","volume":"318","author":"D Dowell","year":"2017","unstructured":"Dowell D, Arias E, Kochanek K, Anderson R, Guy GP Jr, Losby JL, et al. Contribution of opioid-involved poisoning to the change in life expectancy in the United States, 2000-2015. Jama. 2017;318(11):1065\u20137.","journal-title":"Jama."},{"issue":"2","key":"350_CR38","first-page":"56","volume":"39","author":"HM Orpana","year":"2019","unstructured":"Orpana HM, Lang JJ, George D, Halverson J. At-a-glance - the impact of poisoning-related mortality on life expectancy at birth in Canada, 2000 to 2016. Public Health Agency Canada. 2019;39(2):56\u201360.","journal-title":"Public Health Agency Canada"},{"issue":"17","key":"350_CR39","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1056\/NEJMp1800216","volume":"378","author":"E Wood","year":"2018","unstructured":"Wood E. Strategies for reducing opioid-overdose deaths - lessons from Canada. N Engl J Med. 2018;378(17):1565\u20137.","journal-title":"N Engl J Med"},{"key":"350_CR40","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.drugpo.2017.06.005","volume":"46","author":"N Fairbairn","year":"2017","unstructured":"Fairbairn N, Coffin PO, Walley AY. Naloxone for heroin, prescription opioid, and illicitly made fentanyl overdoses: challenges and innovations responding to a dynamic epidemic. Int J Drug Policy. 2017;46:172\u20139.","journal-title":"Int J Drug Policy"},{"issue":"9","key":"350_CR41","doi-asserted-by":"publisher","first-page":"E247","DOI":"10.1503\/cmaj.170958","volume":"190","author":"J Bruneau","year":"2018","unstructured":"Bruneau J, Ahamad K, Goyer M-\u00c8, Poulin G, Selby P, Fischer B, et al. Management of opioid use disorders: a national clinical practice guideline. Can Med Assoc J. 2018;190(9):E247\u2013E57.","journal-title":"Can Med Assoc J"},{"issue":"5","key":"350_CR42","doi-asserted-by":"publisher","first-page":"e218","DOI":"10.1016\/S2468-2667(18)30044-6","volume":"3","author":"MA Irvine","year":"2018","unstructured":"Irvine MA, Buxton JA, Otterstatter M, Balshaw R, Gustafson R, Tyndall M, et al. Distribution of take-home opioid antagonist kits during a synthetic opioid epidemic in British Columbia, Canada: a modelling study. Lancet Public Health. 2018;3(5):e218\u2013e25.","journal-title":"Lancet Public Health"},{"key":"350_CR43","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.drugpo.2019.02.005","volume":"71","author":"C Strike","year":"2019","unstructured":"Strike C, Watson TM. Losing the uphill battle? Emergent harm reduction interventions and barriers during the opioid overdose crisis in Canada. Int J Drug Policy. 2019;71:178\u201382.","journal-title":"Int J Drug Policy"},{"key":"350_CR44","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.drugalcdep.2018.04.024","volume":"189","author":"B Fischer","year":"2018","unstructured":"Fischer B, Varatharajan T, Shield K, Rehm J, Jones W. Crude estimates of prescription opioid-related misuse and use disorder populations towards informing intervention system need in Canada. Drug Alcohol Depend. 2018;189:76\u20139.","journal-title":"Drug Alcohol Depend"},{"key":"350_CR45","doi-asserted-by":"publisher","first-page":"100016","DOI":"10.1016\/j.puhip.2020.100016","volume":"1","author":"B Fischer","year":"2020","unstructured":"Fischer B, Lee A, Vojtila L. \u2018Safer opioid distribution\u2019 as an essential public health intervention for the opioid mortality crisis \u2013 considerations, options and examples towards broad-based implementation. Public Health Pract. 2020;1:100016.","journal-title":"Public Health Pract"},{"issue":"2","key":"350_CR46","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1016\/S2468-2667(18)30232-9","volume":"4","author":"B Fischer","year":"2019","unstructured":"Fischer B, Pang M, Tyndall M. The opioid death crisis in Canada: crucial lessons for public health. Lancet Public Health. 2019;4(2):e81\u2013e2.","journal-title":"Lancet Public Health"},{"issue":"10209","key":"350_CR47","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/S0140-6736(19)32230-5","volume":"394","author":"M Farrell","year":"2019","unstructured":"Farrell M, Martin NK, Stockings E, B\u00f3rquez A, Cepeda JA, Degenhardt L, et al. Responding to global stimulant use: Challenges and opportunities. Lancet (London, England). 2019;394(10209):1652\u201367.","journal-title":"Lancet (London, England)"},{"issue":"10","key":"350_CR48","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1111\/add.14234","volume":"113","author":"A Peacock","year":"2018","unstructured":"Peacock A, Leung J, Larney S, Colledge S, Hickman M, Rehm J, et al. Global statistics on alcohol, tobacco and illicit drug use: 2017 status report. Addiction. 2018;113(10):1905\u201326.","journal-title":"Addiction."},{"key":"350_CR49","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.drugalcdep.2017.08.036","volume":"180","author":"AJ Butler","year":"2017","unstructured":"Butler AJ, Rehm J, Fischer B. Health outcomes associated with crack-cocaine use: systematic review and meta-analyses. Drug Alcohol Depend. 2017;180:401\u201316.","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"350_CR50","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1111\/dar.13062","volume":"39","author":"C Cumming","year":"2020","unstructured":"Cumming C, Kinner SA, McKetin R, Li I, Preen D. Methamphetamine use, health and criminal justice system outcomes: a systematic review. Drug Alcohol Rev. 2020;39(5):505\u201318.","journal-title":"Drug Alcohol Rev"},{"key":"350_CR51","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.eclinm.2019.09.014","volume":"16","author":"R McKetin","year":"2019","unstructured":"McKetin R, Leung J, Stockings E, Huo Y, Foulds J, Lappin JM, et al. Mental health outcomes associated with the use of amphetamines: a systematic review and meta-analysis. EClinicalMedicine. 2019;16:81\u201397.","journal-title":"EClinicalMedicine."},{"key":"350_CR52","doi-asserted-by":"publisher","first-page":"108135","DOI":"10.1016\/j.drugalcdep.2020.108135","volume":"213","author":"JA Cepeda","year":"2020","unstructured":"Cepeda JA, Vickerman P, Bruneau J, Zang G, Borquez A, Farrell M, et al. Estimating the contribution of stimulant injection to HIV and HCV epidemics among people who inject drugs and implications for harm reduction: a modeling analysis. Drug Alcohol Depend. 2020;213:108135.","journal-title":"Drug Alcohol Depend"},{"issue":"12","key":"350_CR53","doi-asserted-by":"publisher","first-page":"349","DOI":"10.15585\/mmwr.mm6712a1","volume":"67","author":"P Seth","year":"2018","unstructured":"Seth P, Scholl L, Rudd RA, Bacon S. Overdose deaths involving opioids, cocaine, and psychostimulants - United States, 2015-2016. Morb Mortal Wkly Rep. 2018;67(12):349\u201358.","journal-title":"Morb Mortal Wkly Rep"},{"key":"350_CR54","doi-asserted-by":"crossref","unstructured":"Cano M, Huang Y. Overdose deaths involving psychostimulants with abuse potential, excluding cocaine: state-level differences and the role of opioids. Drug Alcohol Depend. 2020.","DOI":"10.1016\/j.drugalcdep.2020.108384"},{"key":"350_CR55","unstructured":"CCSUA. Changes in stimulant use and related harms: focus on methamphetamine and cocaine (CCENDU bulletin). Ottawa: Canadian Centre on Substance Use and Addiction; 2019."},{"key":"350_CR56","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.drugalcdep.2018.08.029","volume":"193","author":"MS Ellis","year":"2018","unstructured":"Ellis MS, Kasper ZA, Cicero TJ. Twin epidemics: the surging rise of methamphetamine use in chronic opioid users. Drug Alcohol Depend. 2018;193:14\u201320.","journal-title":"Drug Alcohol Depend"},{"key":"350_CR57","doi-asserted-by":"publisher","first-page":"107592","DOI":"10.1016\/j.drugalcdep.2019.107592","volume":"204","author":"JC Strickland","year":"2019","unstructured":"Strickland JC, Havens JR, Stoops WW. A nationally representative analysis of \u201ctwin epidemics\u201d: rising rates of methamphetamine use among persons who use opioids. Drug Alcohol Depend. 2019;204:107592.","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"350_CR58","doi-asserted-by":"publisher","first-page":"e192851","DOI":"10.1001\/jamanetworkopen.2019.2851","volume":"2","author":"L LaRue","year":"2019","unstructured":"LaRue L, Twillman RK, Dawson E, Whitley P, Frasco MA, Huskey A, et al. Rate of fentanyl positivity among urine drug test results positive for cocaine or methamphetamine. JAMA Netw Open. 2019;2(4):e192851\u2013e.","journal-title":"JAMA Netw Open"},{"issue":"11","key":"350_CR59","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1080\/10826084.2020.1765805","volume":"55","author":"R Daniulaityte","year":"2020","unstructured":"Daniulaityte R, Silverstein SM, Crawford TN, Martins SS, Zule W, Zaragoza AJ, et al. Methamphetamine use and its correlates among individuals with opioid use disorder in a Midwestern U.S. city. Subst Use Misuse. 2020;55(11):1781\u20139.","journal-title":"Subst Use Misuse"},{"issue":"2","key":"350_CR60","doi-asserted-by":"publisher","first-page":"244","DOI":"10.2105\/AJPH.2019.305412","volume":"110","author":"TJ Cicero","year":"2019","unstructured":"Cicero TJ, Ellis MS, Kasper ZA. Polysubstance use: a broader understanding of substance use during the opioid crisis. Am J Public Health. 2019;110(2):244\u201350.","journal-title":"Am J Public Health"},{"issue":"2","key":"350_CR61","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1111\/add.14812","volume":"115","author":"CM Jones","year":"2020","unstructured":"Jones CM, Underwood N, Compton WM. Increases in methamphetamine use among heroin treatment admissions in the United States, 2008\u201317. Addiction. 2020;115(2):347\u201353.","journal-title":"Addiction."},{"issue":"5","key":"350_CR62","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1111\/add.14878","volume":"115","author":"B Hoots","year":"2020","unstructured":"Hoots B, Vivolo-Kantor A, Seth P. The rise in non-fatal and fatal overdoses involving stimulants with and without opioids in the United States. Addiction. 2020;115(5):946\u201358.","journal-title":"Addiction."},{"key":"350_CR63","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jsat.2019.10.005","volume":"109","author":"JI Tsui","year":"2020","unstructured":"Tsui JI, Mayfield J, Speaker EC, Yakup S, Ries R, Funai H, et al. Association between methamphetamine use and retention among patients with opioid use disorders treated with buprenorphine. J Subst Abus Treat. 2020;109:80\u20135.","journal-title":"J Subst Abus Treat"},{"issue":"34","key":"350_CR64","doi-asserted-by":"publisher","first-page":"737","DOI":"10.15585\/mmwr.mm6834a2","volume":"68","author":"RM Gladden","year":"2019","unstructured":"Gladden RM, O'Donnell J, Mattson CL, Seth P. Changes in opioid-involved overdose deaths by opioid yype and presence of benzodiazepines, cocaine, and methamphetamine - 25 states, July-December 2017 to January-June 2018. Morb Mortal Wkly Rep. 2019;68(34):737\u201344.","journal-title":"Morb Mortal Wkly Rep"},{"key":"350_CR65","doi-asserted-by":"publisher","first-page":"388","DOI":"10.15585\/mmwr.mm6817a3","volume":"68","author":"M Kariisa","year":"2019","unstructured":"Kariisa M, Scholl L, Wilson N, Seth P, Hoots B. Drug overdose deaths involving cocaine and psychostimulants with abuse potential - United States, 2003\u20132017. Morb Mortal Wkly Rep. 2019;68:388\u201395.","journal-title":"Morb Mortal Wkly Rep"},{"key":"350_CR66","unstructured":"Hedegaard H, Mini\u00f1o AM, Warner M. Drug overdose deaths in the United States, 1999-2019. NCHS Data Brief. 2020;(394):1\u20138."},{"issue":"7","key":"350_CR67","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1111\/dar.13126","volume":"39","author":"P Bach","year":"2020","unstructured":"Bach P, Hayashi K, Milloy M-J, Nosova E, Kerr T, Wood E, et al. Characterising the increasing prevalence of crystal methamphetamine use in Vancouver, Canada, from 2006\u20132017: a gender-based analysis. Drug Alcohol Rev. 2020;39(7):932\u201340.","journal-title":"Drug Alcohol Rev"},{"key":"350_CR68","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugalcdep.2017.10.020","volume":"183","author":"K Hayashi","year":"2018","unstructured":"Hayashi K, Milloy MJ, Lysyshyn M, DeBeck K, Nosova E, Wood E, et al. Substance use patterns associated with recent exposure to fentanyl among people who inject drugs in Vancouver, Canada: a cross-sectional urine toxicology screening study. Drug Alcohol Depend. 2018;183:1\u20136.","journal-title":"Drug Alcohol Depend"},{"key":"350_CR69","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.drugalcdep.2017.12.032","volume":"185","author":"N Baldwin","year":"2018","unstructured":"Baldwin N, Gray R, Goel A, Wood E, Buxton JA, Rieb LM. Fentanyl and heroin contained in seized illicit drugs and overdose-related deaths in British Columbia, Canada: an observational analysis. Drug Alcohol Depend. 2018;185:322\u20137.","journal-title":"Drug Alcohol Depend"},{"key":"350_CR70","doi-asserted-by":"publisher","first-page":"102617","DOI":"10.1016\/j.drugpo.2019.102617","volume":"76","author":"G Kolla","year":"2020","unstructured":"Kolla G, Kenny KS, Bannerman M, Boyce N, Chapman L, Dodd Z, et al. Help me fix: the provision of injection assistance at an unsanctioned overdose prevention site in Toronto, Canada. Int J Drug Policy. 2020;76:102617.","journal-title":"Int J Drug Policy"},{"issue":"2","key":"350_CR71","doi-asserted-by":"publisher","first-page":"210","DOI":"10.17269\/s41997-019-00180-w","volume":"110","author":"S Bourque","year":"2019","unstructured":"Bourque S, Pijl EM, Mason E, Manning J, Motz T. Supervised inhalation is an important part of supervised consumption services. Can J Public Health. 2019;110(2):210\u20135.","journal-title":"Can J Public Health"},{"key":"350_CR72","unstructured":"Government of Alberta. Impact: A socio-economic review of supervised consumption sites in Alberta. Alberta: Government of Alberta; 2020."},{"key":"350_CR73","unstructured":"CCSUA. Adulterants, contaminants and co-occurring substances in drugs on the illegal market in Canada (CCENDU bulletin).\u00a0Ottawa: Canadian Centre on Substance Use and Addiction; 2020."},{"key":"350_CR74","unstructured":"Government of Canada. Special Advisory Committee on the Epidemic of Opioid Overdoses: Opioids and stimulant-related Harms in Canada 2020 [cited 2021 January, 7]. Available from: https:\/\/health-infobase.canada.ca\/substance-related-harms\/opioids-stimulants."},{"key":"350_CR75","volume-title":"Opioid-related harms in Canada","author":"Government of Canada","year":"2020","unstructured":"Government of Canada. Opioid-related harms in Canada. Ottawa: Public Health Agency of Canada; 2020."},{"issue":"34","key":"350_CR76","doi-asserted-by":"publisher","first-page":"E967","DOI":"10.1503\/cmaj.200191","volume":"192","author":"A Crabtree","year":"2020","unstructured":"Crabtree A, Lostchuck E, Chong M, Shapiro A, Slaunwhite A. Toxicology and prescribed medication histories among people experiencing fatal illicit drug overdose in British Columbia, Canada. Can Med Assoc J. 2020;192(34):E967\u2013E72.","journal-title":"Can Med Assoc J"},{"key":"350_CR77","unstructured":"The Canadian Press. 'It's an epidemic:' Inexpensive crystal meth eclipsing opioids on the Prairies Canada: CBC; 2018. Available from: https:\/\/www.cbc.ca\/news\/canada\/manitoba\/meth-crisis-prairies-1.4881629 [cited 2020 November, 30]."},{"key":"350_CR78","unstructured":"Drug and Alcohol Testing Association of Canada (DATAC). Crystal meth use on the rise in the Prairies Canada.\u00a0Barrie: DATAC; 2018.\u00a0Available from: https:\/\/datac.ca\/crystal-meth-use-on-the-increase-in-the-prairies\/ [cited 2020 November, 30]."},{"issue":"5","key":"350_CR79","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/add.14474","volume":"114","author":"SG Mars","year":"2019","unstructured":"Mars SG, Rosenblum D, Ciccarone D. Illicit fentanyls in the opioid street market: desired or imposed? Addiction. 2019;114(5):774\u201380.","journal-title":"Addiction."},{"key":"350_CR80","unstructured":"United Nations Office on Drugs and Crime (UNODC). World drug report 2020.\u00a0Vienna:\u00a0United Nations Publication; 2020."},{"key":"350_CR81","volume-title":"Impacts of methamphetamine abuse in Canada: report of the standing committee on health","author":"B Casey","year":"2019","unstructured":"Casey B. Impacts of methamphetamine abuse in Canada: report of the standing committee on health. Ottawa: House of Commons; 2019."},{"issue":"1","key":"350_CR82","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12889-020-8205-z","volume":"20","author":"B Fischer","year":"2020","unstructured":"Fischer B, Jones W, Tyndall M, Kurdyak P. Correlations between opioid mortality increases related to illicit\/synthetic opioids and reductions of medical opioid dispensing - exploratory analyses from Canada. BMC Public Health. 2020;20(1):143.","journal-title":"BMC Public Health"},{"issue":"2","key":"350_CR83","doi-asserted-by":"publisher","first-page":"e187621","DOI":"10.1001\/jamanetworkopen.2018.7621","volume":"2","author":"Q Chen","year":"2019","unstructured":"Chen Q, Larochelle MR, Weaver DT, Lietz AP, Mueller PP, Mercaldo S, et al. Prevention of prescription opioid misuse and projected overdose deaths in the United States. JAMA Netw Open. 2019;2(2):e187621\u2013e.","journal-title":"JAMA Netw Open"},{"key":"350_CR84","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.drugalcdep.2019.03.014","volume":"200","author":"JA Barocas","year":"2019","unstructured":"Barocas JA, Wang J, Marshall BDL, LaRochelle MR, Bettano A, Bernson D, et al. Sociodemographic factors and social determinants associated with toxicology confirmed polysubstance opioid-related deaths. Drug Alcohol Depend. 2019;200:59\u201363.","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"350_CR85","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1016\/j.annemergmed.2020.06.046","volume":"76","author":"MC Chawarski","year":"2020","unstructured":"Chawarski MC, Hawk K, Edelman EJ, O\u2019Connor P, Owens P, Martel S, et al. Use of amphetamine-type stimulants among emergency department patients with untreated opioid use disorder. Ann Emerg Med. 2020;76(6):782\u20137.","journal-title":"Ann Emerg Med"},{"issue":"5","key":"350_CR86","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.addbeh.2014.01.018","volume":"39","author":"L-Y Chen","year":"2014","unstructured":"Chen L-Y, Strain EC, Alexandre PK, Alexander GC, Mojtabai R, Martins SS. Correlates of nonmedical use of stimulants and methamphetamine use in a national sample. Addict Behav. 2014;39(5):829\u201336.","journal-title":"Addict Behav"},{"issue":"4","key":"350_CR87","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1037\/1064-1297.13.4.303","volume":"13","author":"F Leri","year":"2005","unstructured":"Leri F, Stewart J, Fischer B, J\u00fcrgen R, Marsh DC, Brissette S, et al. Patterns of opioid and cocaine co-use: a descriptive study in a Canadian sample of untreated opioid-dependent individuals. Exp Clin Psychopharmacol. 2005;13(4):303\u201310.","journal-title":"Exp Clin Psychopharmacol"},{"key":"350_CR88","doi-asserted-by":"crossref","unstructured":"Fischer B, Rehm J, Kim G, Kirst M. Eyes wide shut? \u2013 a conceptual and empirical critique of methadone maintenance treatment. Eur Addict Res 2005;11(1):1\u201314.","DOI":"10.1159\/000081410"},{"key":"350_CR89","doi-asserted-by":"publisher","first-page":"108238","DOI":"10.1016\/j.drugalcdep.2020.108238","volume":"216","author":"T Antoniou","year":"2020","unstructured":"Antoniou T, McCormack D, Campbell T, Sutradhar R, Tadrous M, Lum-Wilson N, et al. Geographic variation in the provision of naloxone by pharmacies in Ontario, Canada: A population-based small area variation analysis. Drug Alcohol Depend. 2020;216:108238.","journal-title":"Drug Alcohol Depend"},{"key":"350_CR90","doi-asserted-by":"publisher","first-page":"108202","DOI":"10.1016\/j.drugalcdep.2020.108202","volume":"216","author":"A Ivsins","year":"2020","unstructured":"Ivsins A, Boyd J, Mayer S, Collins A, Sutherland C, Kerr T, et al. Barriers and facilitators to a novel low-barrier hydromorphone distribution program in Vancouver, Canada: A qualitative study. Drug Alcohol Depend. 2020;216:108202.","journal-title":"Drug Alcohol Depend"},{"key":"350_CR91","unstructured":"Government of Canada. Federal ations on opioids to date Canada.\u00a0Ottawa: Government of Canada; 2020 [Available from: https:\/\/www.canada.ca\/en\/health-canada\/services\/substance-use\/problematic-prescription-drug-use\/opioids\/federal-actions\/overview.html."},{"key":"350_CR92","doi-asserted-by":"publisher","first-page":"k3207","DOI":"10.1136\/bmj.k3207","volume":"362","author":"T Gomes","year":"2018","unstructured":"Gomes T, Khuu W, Martins D, Tadrous M, Mamdani MM, Paterson JM, et al. Contributions of prescribed and non-prescribed opioids to opioid related deaths: population based cohort study in Ontario, Canada. BMJ. 2018;362:k3207.","journal-title":"BMJ"},{"issue":"4","key":"350_CR93","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.drugpo.2015.01.002","volume":"26","author":"B Fischer","year":"2015","unstructured":"Fischer B, Blanken P, Da Silveira D, Gallassi A, Goldner EM, Rehm J, et al. Effectiveness of secondary prevention and treatment interventions for crack-cocaine abuse: a comprehensive narrative overview of English-language studies. Int J Drug Policy. 2015;26(4):352\u201363.","journal-title":"Int J Drug Policy"},{"key":"350_CR94","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jsat.2018.06.001","volume":"91","author":"AR Williams","year":"2018","unstructured":"Williams AR, Nunes EV, Bisaga A, Pincus HA, Johnson KA, Campbell AN, et al. Developing an opioid use disorder treatment cascade: a review of quality measures. J Subst Abus Treat. 2018;91:57\u201368.","journal-title":"J Subst Abus Treat"},{"issue":"2","key":"350_CR95","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1097\/HRP.0000000000000075","volume":"23","author":"HS Connery","year":"2015","unstructured":"Connery HS. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harvard Rev Psychiatry. 2015;23(2):63\u201375.","journal-title":"Harvard Rev Psychiatry"},{"issue":"6","key":"350_CR96","doi-asserted-by":"publisher","first-page":"e0234809","DOI":"10.1371\/journal.pone.0234809","volume":"15","author":"C Ronsley","year":"2020","unstructured":"Ronsley C, Nolan S, Knight R, Hayashi K, Klimas J, Walley A, et al. Treatment of stimulant use disorder: a systematic review of reviews. PLoS One. 2020;15(6):e0234809.","journal-title":"PLoS One"},{"key":"350_CR97","first-page":"1","volume":"9","author":"X Castells","year":"2016","unstructured":"Castells X, Cunill R, P\u00e9rez-Ma\u00f1\u00e1 C, Vidal X, Capell\u00e0 D. Psychostimulant drugs for cocaine dependence. Cochrane Database Syst Rev. 2016;9:1\u2013141.","journal-title":"Cochrane Database Syst Rev."},{"key":"350_CR98","doi-asserted-by":"crossref","unstructured":"P\u00e9rez-Ma\u00f1\u00e1 C, Castells X, Torrens M, Capell\u00e0 D, Farre M. Efficacy of psychostimulant drugs for amphetamine abuse or dependence. Cochrane Database Syst Rev. 2013;9.","DOI":"10.1002\/14651858.CD009695.pub2"},{"issue":"2","key":"350_CR99","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJMoa2020214","volume":"384","author":"MH Trivedi","year":"2021","unstructured":"Trivedi MH, Walker R, Ling W, dela Cruz A, Sharma G, Carmody T, et al. Bupropion and naltrexone in methamphetamine use disorder. N Engl J Med. 2021;384(2):140\u201353.","journal-title":"N Engl J Med"},{"issue":"8","key":"350_CR100","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1007\/s00213-020-05563-3","volume":"237","author":"VS Tardelli","year":"2020","unstructured":"Tardelli VS, Bisaga A, Arcadepani FB, Gerra G, Levin FR, Fidalgo TM. Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis. Psychopharmacology. 2020;237(8):2233\u201355.","journal-title":"Psychopharmacology."},{"key":"350_CR101","unstructured":"Brandt L, Chao T, Comer SD, Levin FR. Pharmacotherapeutic strategies for treating cocaine use disorder\u2014what do we have to offer? Addiction."},{"key":"350_CR102","unstructured":"Humphreys K. Will hope triumph over experience in pharmacotherapy research on cocaine use disorder? Addiction."},{"issue":"9","key":"350_CR103","first-page":"Cd011866","volume":"9","author":"S Minozzi","year":"2016","unstructured":"Minozzi S, Saulle R, De Crescenzo F, Amato L. Psychosocial interventions for psychostimulant misuse. Cochrane Database Syst Rev. 2016;9(9):Cd011866.","journal-title":"Cochrane Database Syst Rev"},{"key":"350_CR104","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugpo.2016.04.013","volume":"34","author":"JF Crepault","year":"2016","unstructured":"Crepault JF, Rehm J, Fischer B. The cannabis policy framework by the Centre for addiction and mental health: a proposal for a public health approach to cannabis policy in Canada. Int J Drug Policy. 2016;34:1\u20134.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"350_CR105","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.jsat.2006.06.012","volume":"32","author":"J Shearer","year":"2007","unstructured":"Shearer J. Psychosocial approaches to psychostimulant dependence: a systematic review. J Subst Abus Treat. 2007;32(1):41\u201352.","journal-title":"J Subst Abus Treat"},{"key":"350_CR106","doi-asserted-by":"crossref","unstructured":"Knapp WP, Soares B, Farrell M, Silva de Lima M. Psychosocial interventions for cocaine and psychostimulant amphetamines related disorders. Cochrane Database Syst Rev. 2007;3.","DOI":"10.1002\/14651858.CD003023.pub2"},{"issue":"3","key":"350_CR107","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1080\/09595230801919494","volume":"27","author":"NK Lee","year":"2008","unstructured":"Lee NK, Rawson RA. A systematic review of cognitive and behavioural therapies for methamphetamine dependence. Drug Alcohol Rev. 2008;27(3):309\u201317.","journal-title":"Drug Alcohol Rev"},{"key":"350_CR108","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.drugalcdep.2016.10.001","volume":"168","author":"C Cumming","year":"2016","unstructured":"Cumming C, Troeung L, Young JT, Kelty E, Preen DB. Barriers to accessing methamphetamine treatment: a systematic review and meta-analysis. Drug Alcohol Depend. 2016;168:263\u201373.","journal-title":"Drug Alcohol Depend"},{"key":"350_CR109","doi-asserted-by":"crossref","unstructured":"Chye Y, Christensen E, Solowij N, Y\u00fccel M. The endocannabinoid system and cannabidiol's promise for the treatment of substance use disorder. Front Psychiatry. 2019;10(63).","DOI":"10.3389\/fpsyt.2019.00063"},{"key":"350_CR110","first-page":"33","volume":"9","author":"M Prud'homme","year":"2015","unstructured":"Prud'homme M, Cata R, Jutras-Aswad D. Cannabidiol as an intervention for addictive behaviors: a systematic review of the evidence. Subst Abus. 2015;9:33\u20138.","journal-title":"Subst Abus"},{"issue":"12","key":"350_CR111","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.drugpo.2015.09.005","volume":"26","author":"B Fischer","year":"2015","unstructured":"Fischer B, Kuganesan S, Gallassi A, Malcher-Lopes R, van den Brink W, Wood E. Addressing the stimulant treatment gap: a call to investigate the therapeutic benefits potential of cannabinoids for crack-cocaine use. Int J Drug Policy. 2015;26(12):1177\u201382.","journal-title":"Int J Drug Policy"},{"key":"350_CR112","doi-asserted-by":"publisher","first-page":"172982","DOI":"10.1016\/j.pbb.2020.172982","volume":"196","author":"LA Rodrigues","year":"2020","unstructured":"Rodrigues LA, Caroba MES, Taba FK, Filev R, Gallassi AD. Evaluation of the potential use of cannabidiol in the treatment of cocaine use disorder: a systematic review. Pharmacol Biochem Behav. 2020;196:172982.","journal-title":"Pharmacol Biochem Behav"},{"key":"350_CR113","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.3390\/molecules24142583","volume":"24","author":"C Calpe-L\u00f3pez","year":"2019","unstructured":"Calpe-L\u00f3pez C, Garc\u00eda-Pardo MP, Aguilar MA. Cannabidiol treatment might promote resilience to cocaine and methamphetamine use disorders: A review of possible mechanisms. Molecules. 2019;24:2583.","journal-title":"Molecules."},{"key":"350_CR114","doi-asserted-by":"crossref","unstructured":"Meneses-Gaya C, Crippa JA, Hallak JE, Miguel AQ, Laranjeira R, Bressan RA, et al. Cannabidiol for the treatment of crack-cocaine craving: An exploratory double-blind study. Braz J Psychiatry. 2020. [e-pub ahead of print 30 Oct 2020].","DOI":"10.1590\/1516-4446-2020-1416"},{"key":"350_CR115","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.addbeh.2017.04.006","volume":"72","author":"ME Soc\u00edas","year":"2017","unstructured":"Soc\u00edas ME, Kerr T, Wood E, Dong H, Lake S, Hayashi K, et al. Intentional cannabis use to reduce crack cocaine use in a Canadian setting: a longitudinal analysis. Addict Behav. 2017;72:138\u201343.","journal-title":"Addict Behav"},{"key":"350_CR116","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1186\/s12889-015-2063-0","volume":"15","author":"JR Gon\u00e7alves","year":"2015","unstructured":"Gon\u00e7alves JR, Nappo SA. Factors that lead to the use of crack cocaine in combination with marijuana in Brazil: a qualitative study. BMC Public Health. 2015;15:706.","journal-title":"BMC Public Health"},{"key":"350_CR117","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3109\/09687637.2010.506898","volume":"18","author":"T Andrade","year":"2011","unstructured":"Andrade T, Santiago L, Amari E, Fischer B. \u2018What a pity!\u2019 \u2013 exploring the use of \u2018pitilho\u2019 as harm reduction among crack users in Salvador, Brazil. Drugs Educ Prev Policy. 2011;18:382\u20136.","journal-title":"Drugs Educ Prev Policy"},{"issue":"5","key":"350_CR118","doi-asserted-by":"publisher","first-page":"e0233463","DOI":"10.1371\/journal.pone.0233463","volume":"15","author":"S Lake","year":"2020","unstructured":"Lake S, Nosova E, Buxton J, Walsh Z, Soc\u00edas ME, Hayashi K, et al. Characterizing motivations for cannabis use in a cohort of people who use illicit drugs: a latent class analysis. PLoS One. 2020;15(5):e0233463.","journal-title":"PLoS One"},{"key":"350_CR119","doi-asserted-by":"publisher","first-page":"102829","DOI":"10.1016\/j.drugpo.2020.102829","volume":"83","author":"M Harris","year":"2020","unstructured":"Harris M. An urgent impetus for action: safe inhalation interventions to reduce COVID-19 transmission and fatality risk among people who smoke crack cocaine in the United Kingdom. Int J Drug Policy. 2020;83:102829.","journal-title":"Int J Drug Policy"},{"issue":"6","key":"350_CR120","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1111\/add.14914","volume":"115","author":"S Imtiaz","year":"2020","unstructured":"Imtiaz S, Strike C, Elton-Marshall T, Rehm J. Safer smoking kits for methamphetamine consumption. Addiction. 2020;115(6):1189\u201390.","journal-title":"Addiction."},{"issue":"4","key":"350_CR121","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1080\/10826084.2018.1528460","volume":"54","author":"J Frankeberger","year":"2019","unstructured":"Frankeberger J, Cepeda A, Natera-Rey G, Valdez A. Safer crack kits and smoking practices: effectiveness of a harm reduction intervention among active crack users in Mexico City. Subst Use Misuse. 2019;54(4):592\u2013600.","journal-title":"Subst Use Misuse"},{"issue":"1","key":"350_CR122","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/s12889-017-4099-9","volume":"17","author":"A Prangnell","year":"2017","unstructured":"Prangnell A, Dong H, Daly P, Milloy MJ, Kerr T, Hayashi K. Declining rates of health problems associated with crack smoking during the expansion of crack pipe distribution in Vancouver, Canada. BMC Public Health. 2017;17(1):163.","journal-title":"BMC Public Health"},{"issue":"1","key":"350_CR123","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12954-017-0144-3","volume":"14","author":"C Strike","year":"2017","unstructured":"Strike C, Watson TM. Education and equipment for people who smoke crack cocaine in Canada: Progress and limits. Harm Reduct J. 2017;14(1):17.","journal-title":"Harm Reduct J"},{"issue":"1","key":"350_CR124","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1747-597X-6-34","volume":"6","author":"L Ti","year":"2011","unstructured":"Ti L, Buxton J, Wood E, Zhang R, Montaner J, Kerr T. Difficulty accessing crack pipes and crack pipe sharing among people who use drugs in Vancouver, Canada. Subst Abuse Treat Prev Policy. 2011;6(1):34.","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"5","key":"350_CR125","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1111\/dar.12815","volume":"37","author":"S Cortina","year":"2018","unstructured":"Cortina S, Kennedy MC, Dong H, Fairbairn N, Hayashi K, Milloy M-J, et al. Willingness to use an in-hospital supervised inhalation room among people who smoke crack cocaine in Vancouver, Canada. Drug Alcohol Rev. 2018;37(5):645\u201352.","journal-title":"Drug Alcohol Rev"},{"issue":"1","key":"350_CR126","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s12954-017-0154-1","volume":"14","author":"T Kerr","year":"2017","unstructured":"Kerr T, Mitra S, Kennedy MC, McNeil R. Supervised injection facilities in Canada: past, present, and future. Harm Reduct J. 2017;14(1):28.","journal-title":"Harm Reduct J"},{"issue":"1","key":"350_CR127","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1186\/s12889-016-3137-3","volume":"16","author":"P Voon","year":"2016","unstructured":"Voon P, Ti L, Dong H, Milloy MJ, Wood E, Kerr T, et al. Risky and rushed public crack cocaine smoking: the potential for supervised inhalation facilities. BMC Public Health. 2016;16(1):476.","journal-title":"BMC Public Health"},{"issue":"1","key":"350_CR128","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12954-020-00414-y","volume":"17","author":"KA Speed","year":"2020","unstructured":"Speed KA, Gehring ND, Launier K, O\u2019Brien D, Campbell S, Hyshka E. To what extent do supervised drug consumption services incorporate non-injection routes of administration? A systematic scoping review documenting existing facilities. Harm Reduct J. 2020;17(1):72.","journal-title":"Harm Reduct J"},{"issue":"2","key":"350_CR129","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.drugpo.2012.09.003","volume":"24","author":"TM Watson","year":"2013","unstructured":"Watson TM, Strike C, Kolla G, Penn R, Jairam J, Hopkins S, et al. Design considerations for supervised consumption facilities (SCFs): preferences for facilities where people can inject and smoke drugs. Int J Drug Policy. 2013;24(2):156\u201363.","journal-title":"Int J Drug Policy"},{"issue":"7","key":"350_CR130","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.drugpo.2015.01.015","volume":"26","author":"R McNeil","year":"2015","unstructured":"McNeil R, Kerr T, Lampkin H, Small W. \u201cWe need somewhere to smoke crack\u201d: an ethnographic study of an unsanctioned safer smoking room in Vancouver, Canada. Int J Drug Policy. 2015;26(7):645\u201352.","journal-title":"Int J Drug Policy"},{"key":"350_CR131","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.drugpo.2019.09.019","volume":"73","author":"A Foreman-Mackey","year":"2019","unstructured":"Foreman-Mackey A, Bayoumi AM, Miskovic M, Kolla G, Strike C. \u2018It's our safe sanctuary\u2019: experiences of using an unsanctioned overdose prevention site in Toronto, Ontario. Int J Drug Policy. 2019;73:135\u201340.","journal-title":"Int J Drug Policy"},{"issue":"1","key":"350_CR132","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s12954-019-0351-1","volume":"17","author":"T Fleming","year":"2020","unstructured":"Fleming T, Barker A, Ivsins A, Vakharia S, McNeil R. Stimulant safe supply: a potential opportunity to respond to the overdose epidemic. Harm Reduct J. 2020;17(1):6.","journal-title":"Harm Reduct J"},{"key":"350_CR133","doi-asserted-by":"publisher","first-page":"102880","DOI":"10.1016\/j.drugpo.2020.102880","volume":"83","author":"M Tyndall","year":"2020","unstructured":"Tyndall M. Safer opioid distribution in response to the COVID-19 pandemic. Int J Drug Policy. 2020;83:102880.","journal-title":"Int J Drug Policy"},{"key":"350_CR134","doi-asserted-by":"publisher","first-page":"102769","DOI":"10.1016\/j.drugpo.2020.102769","volume":"80","author":"A Ivsins","year":"2020","unstructured":"Ivsins A, Boyd J, Beletsky L, McNeil R. Tackling the overdose crisis: the role of safe supply. Int J Drug Policy. 2020;80:102769.","journal-title":"Int J Drug Policy"},{"key":"350_CR135","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.drugpo.2019.03.003","volume":"68","author":"SG Sherman","year":"2019","unstructured":"Sherman SG, Morales KB, Park JN, McKenzie M, Marshall BDL, Green TC. Acceptability of implementing community-based drug checking services for people who use drugs in three United States cities: Baltimore, Boston and Providence. Int J Drug Policy. 2019;68:46\u201353.","journal-title":"Int J Drug Policy"},{"issue":"35","key":"350_CR136","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.15585\/mmwr.mm6935a1","volume":"69","author":"J O'Donnell","year":"2020","unstructured":"O'Donnell J, Gladden RM, Mattson CL, Hunter CT, Davis NL. Vital signs: characteristics of drug overdose deaths involving opioids and stimulants - 24 states and the District of Columbia, January-June 2019. Morb Mortal Wkly Rep. 2020;69(35):1189\u201397.","journal-title":"Morb Mortal Wkly Rep"},{"key":"350_CR137","doi-asserted-by":"crossref","unstructured":"Jones CM, Bekheet F, Park JN, Alexander GC. The evolving overdose epidemic: synthetic opioids and rising stimulant-related harms. Epidemiol Rev. 2020.","DOI":"10.1093\/epirev\/mxaa011"},{"key":"350_CR138","doi-asserted-by":"crossref","unstructured":"Compton WM, Valentino RJ, DuPont RL. Polysubstance use in the U.S. opioid crisis. Mol Psychiatry.\u00a02021;26:41\u201350.","DOI":"10.1038\/s41380-020-00949-3"},{"key":"350_CR139","doi-asserted-by":"publisher","first-page":"108193","DOI":"10.1016\/j.drugalcdep.2020.108193","volume":"216","author":"B Chan","year":"2020","unstructured":"Chan B, Freeman M, Ayers C, Korthuis PT, Paynter R, Kondo K, et al. A systematic review and meta-analysis of medications for stimulant use disorders in patients with co-occurring opioid use disorders. Drug Alcohol Depend. 2020;216:108193.","journal-title":"Drug Alcohol Depend"}],"container-title":["Substance Abuse Treatment, Prevention, and Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13011-021-00350-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13011-021-00350-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13011-021-00350-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,29]],"date-time":"2023-01-29T09:08:00Z","timestamp":1674983280000},"score":1,"resource":{"primary":{"URL":"https:\/\/substanceabusepolicy.biomedcentral.com\/articles\/10.1186\/s13011-021-00350-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,15]]},"references-count":139,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["350"],"URL":"https:\/\/doi.org\/10.1186\/s13011-021-00350-5","relation":{},"ISSN":["1747-597X"],"issn-type":[{"value":"1747-597X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,15]]},"assertion":[{"value":"22 January 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}